




RealRate

PHARMACEUTICAL 2018

Bellicum Pharmaceuticals INC
Rank 196 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bellicum Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellicum Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Bellicum Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 230%, being 22% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	101,650
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,156
Liabilities, Non-Current	34,946
Other Assets	7,936
Other Compr. Net Income	0
Other Expenses	864
Other Liabilities	3,778
Other Net Income	-4,392
Other Revenues	185
Property and Equipment	25,942
Research and Development	65,663
Selling, General and Administrative Expense	21,045

Output Variable	Value in 1000 USD
Assets	135,528
Liabilities	50,880
Expenses	87,572
Revenues	185
Stockholders Equity	84,648
Net Income	-91,779
Comprehensive Net Income	-91,779
BaseVar	139,278
ECR before LimitedLiability	100%
Economic Capital Ratio	230%